Appetite suppressants and valvular heart disease in a population-based sample: The HyperGEN study

American Journal of Medicine

Volumn 112, Issue 9, 2002, Pages 710-715

  Palmieri, Vittorio ^a   Arnett, Donna K ^b   Roman, Mary J ^a   Liu, Jennifer E ^a   Bella, Jonathan N ^a   Oberman, Albert ^c   Kitzman, Dalane W ^d   Hopkins, Paul N ^e   Morgan, Derek ^f   De Simone, Giovanni ^a   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

ADULT; AORTA ROOT; AORTA VALVE REGURGITATION; ARTICLE; CALCIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; VALVULAR HEART DISEASE; VASODILATATION;

AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; DEXFENFLURAMINE; DRUG COMBINATIONS; FEMALE; FENFLURAMINE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHENTERMINE;

EID: 0037096627     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01123-3     Document Type: Article

References (39)

1. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November
2. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group
3. Valvular heart disease associated with fenfluramine-phentermine
4. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group
5. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months
6. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
7. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
8. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
9. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
10. Appetite suppressants and valvular heart disease
11. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
12. The aetiology and course of isolated severe aortic regurgitation: A clinical, pathological, and echocardiographic study
13. Aortic root dilatation as a cause of isolated, severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns, and relation to left ventricular hypertrophy and function
14. Prevalence of aortic regurgitation by color flow Doppler in relation to aortic root size
15. Aortic root dilatation at sinuses of Valsalva and aortic regurgitation in hypertensive and normotensive subjects. The HyperGEN study
16. Two-dimensional echocardiographic aortic root dimensions in normal children and adults
17. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities
18. Determinants of echocardiographic aortic root size. The Framingham Heart Study
19. NHLBI family blood pressure program: Methodology and recruitment in the HyperGEN network. Hypertension Genetic Epidemiology Network
20. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study
21. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
22. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial)
23. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: The Strong Heart Study
24. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques
25. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
26. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study
27. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
28. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence of absence of asynergy
29. In vivo mitral valve morphology and motion in mitral valve prolapse
30. Evaluation of valvular regurgitation by color Doppler
31. Prevalence and correlates of aortic regurgitation in American Indians: The Strong Heart Study
32. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study)
33. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves
34. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin
35. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine
36. Echocardiographic examination of women previously treated with fenfluramine: Long-term follow-up of a randomized, double-blind, placebo-controlled trial
37. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment
38. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
39. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)